-
公开(公告)号：US20180235923A1
公开(公告)日：2018-08-23
申请号：US15894544
申请日：2018-02-12
发明人： Keith CHAN , Winston Town , Shou Shan Chiang
IPC分类号： A61K31/295 , A61K33/26 , A61K9/14 , A61K31/555
CPC分类号： A61K31/295 , A61K9/143 , A61K31/555 , A61K33/26
摘要： The present invention provides methods of treating soft tissue calcification in a subject, comprising a step of administering to said subject an effective amount of ferric organic compound, such as ferric citrate. The claimed methods may prevent, reverse, delay or stabilize soft tissue calcification in a subject having chronic kidney disease. Affected soft tissue calcification includes soft tissue calcification in the joint, skin, eye, in cardiovascular system such as heart valve, myocardium, coronary arteries and arteriole, or in internal organs such as kidney and lung.
-
2.发明申请PHARMACEUTICAL-GRADE FERRIC ORGANIC COMPOUNDS, USES THEREOF AND METHODS OF MAKING SAME 有权药用级有机化合物，其用途及其制备方法公开(公告)号：US20140309298A1
公开(公告)日：2014-10-16
申请号：US14306756
申请日：2014-06-17
发明人： Keith CHAN , Winston Town
IPC分类号： A61K31/295
CPC分类号： A61K33/26 , A61K31/295 , C07C51/412 , C07C51/418 , C07C59/265 , C07C55/10 , C07C59/255 , C07C53/08 , C07C59/245 , C07C57/15
摘要： The present invention discloses a pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels.
摘要翻译： 本发明公开了一种药物级三价铁的有机化合物，包括柠檬酸铁，其在较宽的pH范围内是可溶的，并且具有大的活性表面积。 还公开了制造和质量控制过程，用于制造符合既定制造版本规范的药用级柠檬酸铁。 药物级铁有机化合物适用于治疗以血清磷酸盐水平升高为特征的疾病。
-
3.发明申请公开(公告)号：US20190269722A1
公开(公告)日：2019-09-05
申请号：US16352455
申请日：2019-03-13
IPC分类号： A61K33/26 , C07C59/265 , A61K31/295 , C07C51/41
摘要： The present invention discloses pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels.
-
4.发明申请公开(公告)号：US20180214480A1
公开(公告)日：2018-08-02
申请号：US15699025
申请日：2017-09-08
IPC分类号： A61K33/26 , C07C51/41 , A61K31/295 , C07C59/265 , C07C55/10 , C07C59/255 , C07C53/08 , C07C59/245 , C07C57/15
CPC分类号： A61K33/26 , A61K31/295 , C07C51/412 , C07C51/418 , C07C59/265 , C07C55/10 , C07C59/255 , C07C53/08 , C07C59/245 , C07C57/15
摘要： The present invention discloses pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels.
-
5.发明申请PHARMACEUTICAL-GRADE FERRIC ORGANIC COMPOUNDS, USES THEREOF AND METHODS OF MAKING SAME 有权药用级有机化合物，其用途及其制备方法公开(公告)号：US20160095878A1
公开(公告)日：2016-04-07
申请号：US14701933
申请日：2015-05-01
IPC分类号： A61K33/26
CPC分类号： A61K33/26 , A61K31/295 , C07C51/412 , C07C51/418 , C07C59/265 , C07C55/10 , C07C59/255 , C07C53/08 , C07C59/245 , C07C57/15
摘要： The present invention discloses pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels.
摘要翻译： 本发明公开了包括柠檬酸铁在内的药物级三价铁有机化合物，其在较宽的pH范围内可溶，并且具有大的活性表面积。 还公开了制造和质量控制过程，用于制造符合既定制造版本规范的药用级柠檬酸铁。 药物级铁有机化合物适用于治疗以血清磷酸盐水平升高为特征的疾病。
-
公开(公告)号：US20210299168A1
公开(公告)日：2021-09-30
申请号：US17091090
申请日：2020-11-06
IPC分类号： A61K33/26 , C07C59/265 , C07C51/41 , A61K31/295
摘要： The present invention discloses pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels.
-
公开(公告)号：US20170368016A1
公开(公告)日：2017-12-28
申请号：US15694876
申请日：2017-09-04
发明人： Keith CHAN , Winston TOWN , Shou Shan CHIANG
IPC分类号： A61K31/295 , A61K9/14 , A61K31/555 , A61K33/26
CPC分类号： A61K31/295 , A61K9/143 , A61K31/555 , A61K33/26
摘要： The present invention provides methods of treating soft tissue calcification in a subject, comprising a step of administering to said subject an effective amount of ferric organic compound, such as ferric citrate. The claimed methods may prevent, reverse, delay or stabilize soft tissue calcification in a subject having chronic kidney disease. Affected soft tissue calcification includes soft tissue calcification in the joint, skin, eye, in cardiovascular system such as heart valve, myocardium, coronary arteries and arteriole, or in internal organs such as kidney and lung.
-
公开(公告)号：US20170112876A1
公开(公告)日：2017-04-27
申请号：US15401452
申请日：2017-01-09
发明人： Keith CHAN
IPC分类号： A61K33/26 , G01N33/50 , A61K31/555 , G01N33/84
CPC分类号： A61K33/26 , A61K31/555 , G01N33/502 , G01N33/84 , G01N2500/10 , G01N2800/347
摘要： A method of selecting or determining a candidate compound suitable for use as a phosphate binder is disclosed. The candidate compound includes ferric compounds, ferric compound complexes, and their derivatives, salts, analogs, and metabolites. The effectiveness of the candidate compound as a phosphate binder is evaluated by a method, comprising measuring and correlating reduction of phosphate concentration in solution and reduction of phosphate absorption in cells.
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.014 秒)
